#KMTS

@haber3com.bsky.social

1 month ago

Yastık altında altın biriktirenler dikkat! Bakanlık iddialara tek tek yanıt verdi Hazine ve Maliye Bakanlığı, Darphane'nin hayata geçireceği Kıymetli Maden Takip Sistemi'nin (KMTS) yastık altı birikimi olan vatandaşları olumsuz etkileyeceği iddialarına yanıt verdi.

Hazine ve Maliye Bakanlığı, Darphane'nin hayata geçireceği Kıymetli Maden Takip Sistemi'nin (KMTS) yastık altı birikimi olan vatandaşları olumsuz etkileyeceği iddialarına yanıt verdi. #Hazine #Maliye #Darphane #KıymetliMaden #KMTS

0 0 0 0

OLAYNET.NET

@olaynet.bsky.social

2 months ago

Altın ticaretinde yeni dönem… - OLAY NET Ekonomide uygulanan sıkı politikalar kapsamında kayıt dışı işlemleri azaltmak, sahte altın ticaretini önlemek için yeni bir gelişme yaşandı.

Altın ticaretinde yeni dönem… olaynet.net/2026/01/alti... #altın #darphane #hazine ve maliye bakanlığı #kayıt dışı ekonomi #kmts #kuyumculuk #sahte altın #Ekonomi

1 0 0 0

AMED RADYO TV

@amedradyotv.bsky.social

2 months ago

Altında yeni dönem: Nakit satış sona eriyor Türkiye'de mücevher ve kuyumculuk sektöründe sahteciliği ve kayıt dışılığı önlemek amacıyla geliştirilen Kıymetli Metal Takip Sistemi'nin (KMTS) nisan ayında hayata geçirilmesi bekleniyor.

Türkiye’de mücevher ve kuyumculuk sektöründe sahtecilik ve kayıt dışılığın önüne geçmek amacıyla hazırlanan **Kıymetli Metal Takip Sistemi (KMTS)**nin nisan ayında devreye alınması planlanıyor.
#ALTIN #tuerkiye #KMTS #nakitsatış
www.tigrishaber.com/altinda-yeni...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Kestra Medical Technologies Reports Second Quarter Fiscal 2026 Financial Results Kestra Medical Technologies (Nasdaq: KMTS) reported Q2 FY2026 results for the period ended October 31, 2025: revenue $22.6M (+53% YoY), ASSURE prescriptions 4,696 (+54% YoY), and gross margin 50.6% (vs 39.6% prior year). GAAP net loss was $32.8M and adjusted EBITDA loss was $19.7M. Kestra raised FY26 revenue guidance to $91M (+52% vs FY25). Cash and cash equivalents were $175M as of Oct 31, 2025; the company also received $148M net proceeds from a Dec 4, 2025 public offering.The company cited commercial expansion, improved revenue cycle management, and a stronger in-network mix as drivers of performance.

#KMTS Kestra Medical Technologies Reports Second Quarter Fiscal 2026 Financial Results

www.stocktitan.net/news/KMTS/kestra-medical...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Kestra Medical Technologies, Ltd. Announces Pricing of Upsized Primary Public Offering of Common Shares Kestra Medical Technologies (Nasdaq: KMTS) priced an upsized underwritten public offering of 6,000,000 common shares at $23.00 per share, producing expected gross proceeds of $138,000,000.The company granted the underwriters a 30-day option to buy up to 900,000 additional shares at the offering price less discounts. The offering is expected to close on December 4, 2025, subject to customary closing conditions. A registration statement was declared effective on December 2, 2025.

#KMTS Kestra Medical Technologies, Ltd. Announces Pricing of Upsized Primary Public Offering of Common Shares

www.stocktitan.net/news/KMTS/kestra-medical...

1 0 0 0

StockTitan

@stocktitan.net

3 months ago

Kestra Medical Technologies, Ltd. Announces Primary Public Offering of Common Shares Kestra Medical Technologies (Nasdaq: KMTS) announced a proposed underwritten public offering of 5,500,000 common shares with a 30-day underwriter option to purchase up to an additional 825,000 shares, subject to market conditions and SEC effectiveness of the registration statement (as of Dec 1, 2025).The company intends to use proceeds to support sales and marketing, ongoing commercialization, further fund research, development and clinical studies, and for working capital and general corporate purposes. All offered shares are being sold by Kestra. Bookrunners include BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs and Wells Fargo Securities. The offering may not occur and terms may change.

#KMTS Kestra Medical Technologies, Ltd. Announces Primary Public Offering of Common Shares

www.stocktitan.net/news/KMTS/kestra-medical...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Kestra Medical Technologies Reports Preliminary Second Quarter Fiscal 2026 Financial Results Kestra Medical Technologies (Nasdaq: KMTS) reported preliminary Q2 fiscal 2026 results for the quarter ended October 31, 2025, showing continued commercial momentum in the wearable defibrillator market. Revenue is expected to be $22.2–$22.6M, up ~52% at the midpoint versus prior year. Gross profit is expected to be $11.0–$11.4M and gross margin is expected near 50.0% versus 39.6% prior year. Loss from operations is expected to be $31.6–$32.0M. Cash and cash equivalents are expected to be approximately $175M. Results are preliminary and subject to adjustment; final results will appear in the Form 10-Q filed in December 2025.

#KMTS Kestra Medical Technologies Reports Preliminary Second Quarter Fiscal 2026 Financial Results

www.stocktitan.net/news/KMTS/kestra-medical...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra’s ASSURE Device Kestra Medical Technologies (Nasdaq: KMTS) announced primary results from ACE-PAS, the largest prospective real-world study of wearable defibrillators, presented at AHA Scientific Sessions 2025.The study enrolled 21,612 patients and showed 100% successful conversion of VT/VF events versus the prespecified goal; an inappropriate-shock rate of 0.0065 per patient-month; 94% of patients had no false positive shock alarms; 2.6% experienced at least one life-threatening VT/VF; ASSURE detected 4.2% high-rate atrial fibrillation (35% newly diagnosed) and 0.3% severe bradycardia/asystole. Median wear time exceeded 23 hours/day, with one-third using the device beyond 90 days.

#KMTS Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra’s ASSURE Device

www.stocktitan.net/news/KMTS/largest-real-w...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results Kestra Medical Technologies (Nasdaq: KMTS) reported strong Q1 FY26 financial results, with revenue reaching $19.4 million, a 52% increase year-over-year. The wearable medical device company saw significant growth with 4,205 prescriptions written for its ASSURE® system, up 51% from the previous year. Gross margin expanded to 45.7% from 32.9% year-over-year.The company raised its FY26 revenue guidance to $88 million, representing 47% growth compared to FY25, up from previous guidance of $85 million. Despite strong top-line growth, Kestra reported a GAAP net loss of $25.8 million and held cash and equivalents of $201.2 million as of July 31, 2025.

#KMTS Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results

www.stocktitan.net/news/KMTS/kestra-medical...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2025 Financial Results Kestra Medical Technologies (NASDAQ:KMTS), a wearable medical device company, reported strong Q4 and FY2025 results. Q4 revenue reached $17.2 million, up 71% year-over-year, while FY25 revenue hit $59.8 million, a 115% increase from FY24. The company's ASSURE® cardiac recovery system saw 13,193 prescriptions in FY25, up 72% from the previous year.Gross margins significantly improved to 44.3% in Q4 FY25 from 13.9% in the prior year, and 40.5% for FY25 compared to 1.3% in FY24. Despite growth, the company reported a GAAP net loss of $51.1 million in Q4 and $113.8 million for FY25. Looking ahead, Kestra projects FY26 revenue of $85 million, representing 42% growth. [ "Revenue grew 115% year-over-year to $59.8 million in FY25", "Significant gross margin expansion to 40.5% in FY25 from 1.3% in FY24", "Strong prescription growth with 13,193 ASSURE® system prescriptions in FY25, up 72%", "Robust cash position of $237.6 million as of April 30, 2025", "Projected 42% revenue growth for FY26 with $85 million guidance" ]

#KMTS Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2025 Financial Results

www.stocktitan.net/news/KMTS/kestra-medical...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Medical Device Leader Kestra Achieves Major Milestone: Added to $10.6T Russell Indexes Post-IPO Fresh from March IPO, Kestra Medical Technologies gains institutional visibility through Russell indexes inclusion. See how this impacts $10.6T in benchmarked assets.

#KMTS Kestra Medical Technologies Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

www.stocktitan.net/news/KMTS/kestra-medical...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Mon Jun 2nd - #REFI #PACK #ONIT #MSB #JILL #IIM #HLX #EVC #CLB #BHLB #AMRC #PDYN #OCFC #NCTY #KMTS #INM #HCSG #FBNC #CCCC #BCBP #AMWD #SLS #TIL #VSTM #ZTEK - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Revolutionary Wearable Defibrillator System Takes Center Stage at Heart Rhythm 2025: Real-World Data Revealed Discover breakthrough ASSURE system combining defibrillation therapy with advanced diagnostics. New clinical data shows real-world impact on cardiac arrest survival. Get Details.

#KMTS Kestra Medical Technologies to Showcase Innovation in Sudden Cardiac Arrest Protection and Recovery at Heart Rhythm 2025

www.stocktitan.net/news/KMTS/kestra-medical...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Kestra Medical Technologies Reports Third Quarter Fiscal 2025 Financial Results Kestra Medical Technologies (NASDAQ: KMTS) reported strong Q3 FY25 financial results with revenue of $15.1 million, up 82% year-over-year. The company achieved a significant improvement in gross margin to 43.4% from 10.6% in the prior year period.Key highlights include 3,459 prescriptions written for the ASSURE® system, representing a 51% increase. The company successfully completed its IPO in March 2025, raising $205.2 million in net proceeds. Kestra expanded its insurance coverage network, now reaching over 285 million health plan members in the United States.For fiscal year 2025 ending April 30, Kestra projects revenue between $58.0-58.5 million, indicating approximately 109-110% growth compared to FY24. However, the company reported a GAAP net loss of $21.8 million and an adjusted EBITDA loss of $16.3 million for Q3 FY25.

#KMTS Kestra Medical Technologies Reports Third Quarter Fiscal 2025 Financial Results

www.stocktitan.net/news/KMTS/kestra-medical...

0 0 0 0